索引于
  • 学术期刊数据库
  • 打开 J 门
  • Genamics 期刊搜索
  • 期刊目录
  • 中国知网(CNKI)
  • 西马戈
  • 乌尔里希的期刊目录
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-WorldCat
  • 普布隆斯
  • 米亚尔
  • 大学教育资助委员会
  • 日内瓦医学教育与研究基金会
  • 欧洲酒吧
  • 谷歌学术
分享此页面

抽象的

Effective SARS-CoV-2 Vaccines on the Horizon

Soma Ghosh1, Prasanta Kumar Ghosh2*

Novel coronavirus identified as SARS-CoV-2 has brought unprecedented sufferings to people in almost all countries across the globe during the recent time. Efforts are continued to develop effective vaccines against the disease. Presently, the efforts of six groups namely, University of Oxford, Oxford, UK; Sinovac, China; Moderna Inc., USA; Wuhan Institute, China; Beijing Institute, China; and Bio N Tech, Germany are more significant. Noteworthy progress in the development of vaccines is in sight, and by the mid-2021 new vaccines may start appearing in the market. All these six vaccines are deployed through intramuscular route. There are a few others which are in the developmental stage and are to be delivered through intradermal, intranasal and event through the oral route. Specialized adjuvants have been used to elicit stronger immune response in certain types of candidates. Sensitized immune cells and genetically modified cells are also being experimented upon to contain the virus through immunological mode.